Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback